Skip to main content
. 2024 Jan 11;12(1):158. doi: 10.3390/biomedicines12010158

Figure 3.

Figure 3

Main results of clinical response and clinical and endoscopic remission between proton pump inhibitor users and non-users during vedolizumab therapy: (a,b) clinical response at weeks 14 and 54 in PPI users vs. non-users; (c,d) clinical remission at weeks 14 and 54 in PPI users vs. non-users; (e,f) endoscopic remission at weeks 14 and 54 in PPI users vs. non-users.